MT119, a new planar-structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation

International Journal of Cancer

Volumn 129, Issue 1, 2011, Pages 214-224

  Zhang, Zhixiang ^a   Meng, Tao ^a   Yang, Na ^a   Wang, Wei ^a   Xiong, Bing ^a   Chen, Yi ^a   Ma, Lanping ^a   Shen, Jingkang ^a   Miao, Ze Hong ^a   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

mitosis; spindle assembly; the colchicine site; tubulin

Indexed keywords

6 [2 (4 METHOXYPHENYL)ETHYL] 9 [(PYRIDINE 3 YLMETHYL)AMINO]PYRIDO[2',1':2,3]IMIDAZO[4,5 C]ISOQUINOLIN 5(6H) ONE; ANTIMITOTIC AGENT; COLCHICINE; DOXORUBICIN; MITOXANTRONE; MT 119; TUBULIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DISRUPTION; CELL PROLIFERATION; DRUG BINDING SITE; DRUG CROSS REACTIVITY; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG TARGETING; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MITOSIS SPINDLE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN POLYMERIZATION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; COLCHICINE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MITOSIS; MOLECULAR STRUCTURE; PROTEIN BINDING; SURFACE PLASMON RESONANCE; TUBULIN;

EID: 79955432079     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25661     Document Type: Article

References (50)

1. Jordan MA, Wilson L,. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-65. (Pubitemid 38525281)
2. Wood KW,. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol 2001; 1: 370-7. (Pubitemid 33585986)
3. Zhang LH, Wu L, Raymon HK, Chen RS, Corral L, Shirley MA, Narla RK, Gamez J, Muller GW, Stirling DI, Bartlett JB, Schafer PH, et al. The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity. Cancer Res 2006; 66: 951-9. (Pubitemid 43165963)
4. Wang G, Shang L, Burgett AW, Harran PG, Wang X,. Diazonamide toxins reveal an unexpected function for ornithine delta-amino transferase in mitotic cell division. Proc Natl Acad Sci U S A 2007; 104: 2068-73. (Pubitemid 46391353)
5. Meng T, Zhang Z, Hu D, Lin L, Ding J, Wang X, Shen J,. Three-component combinatorial synthesis of a substituted 6H-pyrido[2',1':2,3]imidazo- [4,5-c]isoquinolin-5(6H)-one library with cytotoxic activity. J Comb Chem 2007; 9: 739-41.
6. Zhang Z, Meng T, He J, Li M, Tong LJ, Xiong B, Lin L, Shen J, Miao ZH, Ding J,. MT7, a novel compound from a combinatorial library, arrests mitosis via inhibiting the polymerization of microtubules. Invest New Drugs 2009 (in press).
7. Harker WG, Slade DL, Dalton WS, Meltzer PS, Trent JM,. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res 1989; 49: 4542-9. (Pubitemid 19208359)
8. Zhu H, Huang M, Yang F, Chen Y, Miao ZH, Qian XH, Xu YF, Qin YX, Luo HB, Shen X, Geng MY, Cai YJ, et al. R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II. Mol Cancer Ther 2007; 6: 484-95. (Pubitemid 46332450)
9. Miao ZH, Tang T, Zhang YX, Zhang JS, Ding J,. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. Int J Cancer 2003; 106: 108-15. (Pubitemid 36750396)
10. Huang M, Gao H, Chen Y, Zhu H, Cai Y, Zhang X, Miao Z, Jiang H, Zhang J, Shen H, Lin L, Lu W, et al. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Clin Cancer Res 2007; 13: 1298-307. (Pubitemid 46424071)
11. Shelanski ML, Gaskin F, Cantor CR,. Microtubule assembly in the absence of added nucleotides. Proc Natl Acad Sci U S A 1973; 70: 765-8.
12. Zhuang SH, Hung YE, Hung L, Robey RW, Sackett DL, Linehan WM, Bates SE, Fojo T, Poruchynsky MS,. Evidence for microtubule target engagement in tumors of patients receiving ixabepilone. Clin Cancer Res 2007; 13: 7480-6.
13. Bravman T, Bronner V, Lavie K, Notcovich A, Papalia GA, Myszka DG,. Exploring "one-shot" kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Anal Biochem 2006; 358: 281-8. (Pubitemid 44573078)
14. Borisy GG,. A rapid method for quantitative determination of microtubule protein using DEAE-cellulose filters. Anal Biochem 1972; 50: 373-85.
15. Ravelli RBG, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M,. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004; 428: 198-202. (Pubitemid 38374318)
16. Garrett M,., Morris DSG, Robert S,., Halliday, Ruth Huey, William E,., Hart, Richard K. Belew, Arthur J. Olson,. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998; 19: 1639-62. (Pubitemid 128590223)
17. Ruth Huey GMM, Olson AJ, Goodsell DS,. A semiempirical free energy force field with charge-based desolvation. J Comput Chem 2007; 28: 1145-52. (Pubitemid 46506716)
18. Xie H, Qin YX, Zhou YL, Tong LJ, Lin LP, Geng MY, Duan WH, Ding J,. GA3, a new gambogic acid derivative, exhibits potent antitumor activities in vitro via apoptosis-involved mechanisms. Acta Pharmacol Sin 2009; 30: 346-54.
19. Qing C, Miao ZH, Tong LJ, Zhang JS, Ding J,. Actinomycin D inhibiting K562 cell apoptosis elicited by salvicine but not decreasing its cytotoxicity. Acta Pharmacol Sin 2003; 24: 415-21.
20. Meng LH, He XX, Zhang JS, Ding J,. DNA topoisomerase II as the primary cellular target for salvicine in Saccharomyces cerevisiae. Acta Pharmacol Sin 2001; 22: 741-6. (Pubitemid 32772420)
21. Bravman T, Bronner V, Lavie K, Notcovich A, Papalia GA, Myszka DG,. Exploring "one-shot" kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Anal Biochem 2006; 358: 281-8. (Pubitemid 44573078)
22. Kalie E, Jaitin DA, Podoplelova Y, Piehler J, Schreiber G,. The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem 2008; 283: 32925-36.
23. Tenhumberg S, Waetzig GH, Chalaris A, Rabe B, Seegert D, Scheller J, Rose-John S, Grotzinger J,. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. J Biol Chem 2008; 283: 27200-7.
24. Tong YG, Zhang XW, Geng MY, Yue JM, Xin XL, Tian F, Shen X, Tong LJ, Li MH, Zhang C, Li WH, Lin LP, et al. Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin. Mol Pharmacol 2006; 69: 1226-33.
25. Banerjee M, Poddar A, Mitra G, Surolia A, Owa T, Bhattacharyya B,. Sulfonamide drugs binding to the colchicine site of tubulin: thermodynamic analysis of the drug-tubulin interactions by isothermal titration calorimetry. J Med Chem 2005; 48: 547-55. (Pubitemid 40139797)
26. Gupta S, Chakraborty S, Poddar A, Sarkar N, Das KP, Bhattacharyya B,. BisANS binding to tubulin: isothermal titration calorimetry and the site-specific proteolysis reveal the GTP-induced structural stability of tubulin. Proteins 2003; 50: 283-9. (Pubitemid 36055606)
27. Mellon MG, Rebhun LI,. Sulfhydryls and the in vitro polymerization of tubulin. J Cell Biol 1976; 70: 226-38.
28. Roychowdhury M, Sarkar N, Manna T, Bhattacharyya S, Sarkar T, Basusarkar P, Roy S, Bhattacharyya B,. Sulfhydryls of tubulin. A probe to detect conformational changes of tubulin. Eur J Biochem 2000; 267: 3469-76. (Pubitemid 30423006)
29. Britto PJ, Knipling L, McPhie P, Wolff J,. Thiol-disulphide interchange in tubulin: kinetics and the effect on polymerization. Biochem J 2005; 389: 549-58. (Pubitemid 41021158)
30. Mooberry SL, Weiderhold KN, Dakshanamurthy S, Hamel E, Banner EJ, Kharlamova A, Hempel J, Gupton JT, Brown ML,. Identification and characterization of a new tubulin-binding tetrasubstituted brominated pyrrole. Mol Pharmacol 2007; 72: 132-40. (Pubitemid 46998532)
31. Smith CD, Zhang X,. Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin. J Biol Chem 1996; 271: 6192-8. (Pubitemid 26098621)
32. Zhang X, Smith C,. Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance. Mol Pharmacol 1996; 49: 288-94. (Pubitemid 26066869)
33. Nguyen TL, McGrath C, Hermone AR, Burnett JC, Zaharevitz DW, Day BW, Wipf P, Hamel E, Gussio R,. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem 2005; 48: 6107-16. (Pubitemid 41324618)
34. Xiao D, Deguchi A, Gundersen GG, Oehlen B, Arnold L, Weinstein IB,. The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization. Mol Cancer Ther 2006; 5: 60-7.
35. Boy O, Brossi A, Arnold B, Geoffrey AC,. Chapter 3 Tropolonic colchicum alkaloids and allo congeners the alkaloids: chemistry and pharmacologyed, vol. 41. Academic Press, 1992. 125-76.
36. Zhou J, Yao J, Joshi HC,. Attachment and tension in the spindle assembly checkpoint. J Cell Sci 2002; 115: 3547-55.
37. Wittmann T, Hyman A, Desai A,. The spindle: a dynamic assembly of microtubules and motors. Nat Cell Biol 2001; 3: E28-34. (Pubitemid 32114823)
38. Mayer TU,. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999; 286: 971-4.
39. Rieder CL, Maiato H,. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004; 7: 637-51. (Pubitemid 39462685)
40. Kadura S, Sazer S,. SAC-ing mitotic errors: how the spindle assembly checkpoint (SAC) plays defense against chromosome mis-segregation. Cell Motil Cytoskeleton 2005; 61: 145-60. (Pubitemid 40923382)
41. Olmsted JB, Borisy GG,. Characterization of microtubule assembly in porcine brain extracts by viscometry. Biochemistry 1973; 12: 4282-9.
42. Sternlicht H, Ringel I,. Colchicine inhibition of microtubule assembly via copolymer formation. J Biol Chem 1979; 254: 10540-50. (Pubitemid 10180993)
43. Margolis RL, Wilson L,. Addition of colchicine - tubulin complex to microtubule ends: the mechanism of substoichiometric colchicine poisoning. Proc Natl Acad Sci USA 1977; 74: 3466-70. (Pubitemid 8177798)
44. Risinger AL, Giles FJ, Mooberry SL,. Microtubule dynamics as a target in oncology. Cancer Treat Rev 2009; 35: 255-61.
45. Kerfant BG, Vassort G, Gomez AM,. Microtubule disruption by colchicine reversibly enhances calcium signaling in intact rat cardiac myocytes. Circ Res 2001; 88: E59-65.
46. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest EE,. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006; 24: 1491-8. (Pubitemid 46638769)
47. LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, DeLuca PA, Evelhoch JL, Boerner SA, Wheeler C,. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 2008; 26: 159-67.
48. Fox E, Maris JM, Widemann BC, Meek K, Goodwin A, Goodspeed W, Kromplewski M, Fouts ME, Medina D, Cho SY, Cohn SL, Krivoshik A, et al. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006; 12: 4882-7. (Pubitemid 44338575)
49. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM,. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003; 21: 2815-22. (Pubitemid 46621828)
50. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21: 4428-38. (Pubitemid 46621821)